Retatrutide
LY3437943 (triple agonist)
Retatrutide is an investigational <b>triple hormone-receptor agonist</b> — it activates GIP, GLP-1 and glucagon receptors at once, making it the most ambitious incretin drug in late-stage development. In 2026 Phase 3 TRIUMPH trials it produced some of the largest weight-loss numbers ever reported for a medication. This guide covers how retatrutide works, what the trials showed, where it stands in development, safety, and how it compares to semaglutide and tirzepatide. Retatrutide is not yet approved — this is educational information, not medical advice.
Retatrutide quick facts
| Reported research dosing | 0.5mg-12mg |
| Route | Subq |
| Cycle length | As Long As Needed |
| Frequency | 1-2x Weekly (Split Dose) |
| Half-life | ~6 days |
| Forms | Injectable |
| Evidence level | Phase 2 human (strong; ~24% weight loss) |
The most exciting fat-loss compound out right now. Titrate slowly — side effects track with jumping dose too fast.
How retatrutide works
Retatrutide is a single once-weekly molecule that activates three receptors: GLP-1 (appetite, gastric emptying, insulin), GIP (insulin-sensitizing, metabolic), and — the differentiator — glucagon. The glucagon arm is thought to increase energy expenditure and drive hepatic (liver) fat loss on top of the appetite suppression the other two provide. Hitting all three incretin/metabolic pathways is the theory behind its outsized effect.
What the research shows
The Phase 3 TRIUMPH program has delivered striking numbers. TRIUMPH-2 (reported January 2026) showed a ~24.2% mean body-weight reduction at 72 weeks on the 12 mg dose versus 2.1% for placebo; TRIUMPH-4 reported ~28.7% at 68 weeks on 12 mg in a population with obesity and knee osteoarthritis; and TRIUMPH-1 met its primary obesity endpoints across 4, 9 and 12 mg doses at 80 weeks. In type 2 diabetes (TRANSCEND-T2D-1), it delivered A1C reductions up to ~2.0% with meaningful weight loss. Several more Phase 3 readouts were expected through 2026.
Where retatrutide stands (development status)
Crucially, retatrutide is investigational — not yet FDA-approved. It is being developed by Eli Lilly and, as of 2026, is completing its Phase 3 program ahead of any regulatory submission. That means there is no approved retatrutide product, no approved dosing, and the long-term safety picture is still being built. Anything sold as 'retatrutide' outside a clinical trial is unapproved.
Safety & what's still unknown
In trials the side-effect profile has looked like the incretin class — predominantly gastrointestinal (nausea, vomiting, diarrhea), most pronounced during dose escalation. Because it adds glucagon-receptor activity, researchers are watching effects on heart rate and glucose closely. The honest bottom line: retatrutide is promising but unproven long-term, and its full safety profile won't be clear until the Phase 3 program and regulatory review are complete.
Retatrutide vs semaglutide vs tirzepatide
This is the three-generation story of incretin therapy. Semaglutide hits one pathway (~15–21%). Tirzepatide hits two (~20–22.5%). Retatrutide hits three and has shown ~24–30% in trials — the largest of the group. But it's also the least mature: semaglutide and tirzepatide are FDA-approved with years of real-world data, while retatrutide is still investigational.
Important safety & legal note
Because retatrutide is not approved, there is no legitimate prescription pathway outside a clinical trial, and any product marketed as retatrutide is unapproved and unregulated. The FDA has broadly warned about unapproved GLP-1-class products. This page is educational only and is not a recommendation to obtain or use retatrutide.
✅ Clinically validated
- Phase 2 produced the largest weight loss recorded for any drug in a randomised trial — 24.2% at 48 weeks at the 12 mg dose, with the curve still falling at the end of the study. Phase 3 (TRIUMPH) is running.
- Not approved anywhere. A phase 2 result is a strong signal and not a licence: the safety profile at scale, over years, in unselected people is exactly what phase 3 exists to find.
📊 Correlative data
- Widely used ahead of approval through research channels. Reported experience tracks the trial — very strong appetite suppression, and a noticeably higher rate of the heart-rate increase seen in the published data.
- Beyond that, the record is self-reported. Community dosing logs are real information about tolerability and nothing at all about efficacy: nobody posts the cycle where they felt no different, so what survives is a filtered sample that will always look better than the truth.
🧪 Theoretical / extrapolated
- A triple agonist: GLP-1, GIP and glucagon. The glucagon arm is the novel part and the reason for the effect size — glucagon receptor agonism raises energy expenditure rather than only reducing intake, so this attacks both sides of the balance where the dual and single agonists attack one.
- The same glucagon activity predicts the two things to watch: raised heart rate, and effects on hepatic glucose output that make it less predictable in someone with unstable glycaemic control.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
Retatrutide — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- These slow gastric emptying and act on hypothalamic and brainstem appetite centres. Almost everything that goes wrong follows from the gastric emptying, not from anything exotic: nausea, early fullness, reflux, constipation, and — when someone titrates faster than their gut adapts — vomiting.
- The composition risk is the one nobody warns about. Appetite suppression does not discriminate. It suppresses the appetite for protein too, and in a deficit without adequate protein and a resistance stimulus a meaningful share of the loss is lean mass. That lowers the maintenance intake you eventually eat back into, which is the mechanism behind most of the rebound stories.
- Slowed emptying also delays absorption of anything else taken by mouth — a pharmacokinetic consequence rather than a drug interaction, but it matters for anything time-critical.
What has actually been reported
- GI effects are extremely common and mostly settle over weeks. Gallbladder problems are a recognised signal, and rapid weight loss of any cause raises gallstone risk — the drug is not doing something unusual, it is doing rapid weight loss well.
- Pancreatitis is reported and rare. The presentation to know is severe upper abdominal pain radiating to the back, usually with vomiting.
- A thyroid C-cell tumour signal exists in rodents and has not been demonstrated in humans; it is why the labelled contraindication for medullary thyroid carcinoma and MEN2 exists.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Follow the titration schedule even if you feel fine. It exists for gut adaptation, not for legal cover. Almost everyone who quits in the first month escalated faster than their stomach could keep up.
- Hit your protein target first at every meal, before anything else on the plate. This is the single highest-leverage habit on the drug — 1.6–2.2 g/kg, and eat it while you still have the appetite to.
- Lift while you are on it. The compound handles intake; resistance training is the only thing handling what you keep.
- Aim for 0.5–1% of bodyweight per week, deliberately. The drug removes the hunger signal that would normally stop you going too hard, so the rate has to be a decision rather than a by-product.
- Fibre and electrolytes from day one, not from week four when constipation has already made up your mind about the drug.
- If nausea is winning, step back one dose rather than quitting the class. Almost nobody needs to be at the top of the range.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- HbA1c and fasting glucose should improve — that is the drug working, and it is the cleanest confirmation you have.
- Rapid loss moves lipids, liver enzymes and uric acid transiently. A wobble at 8 weeks into aggressive loss is usually the loss, not a new problem — but it is a reason to have the baseline.
- Worth a thyroid panel and a lipid panel before starting, simply so a later result has something to be compared against.
Don't run this if
- Personal or family history of medullary thyroid carcinoma, or MEN2.
- Previous pancreatitis.
- Active gastroparesis — you would be adding a drug whose main action is the thing already wrong.
The honest unknown
- What happens to body composition over repeated multi-year cycles of loss and regain on and off these drugs. Weight is well studied; the muscle-to-fat ratio of what comes back is not.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Any time — but the same day each week
With a half-life measured in days you are dosing into a standing level, so the hour is irrelevant and the consistency is not. Pick a day and hold it; drifting the interval is what produces the peaks and troughs people mistake for the drug not working.
Food makes no meaningful difference at this half-life.
Derived from half-life, route and mechanism — not from a dosing trial. Reasoned, and labelled as reasoned.
Retatrutide reconstitution calculator
Research reconstitution calculator
Where to get Retatrutide
Buy Retatrutide at AminoWell USA →Retatrutide — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What Retatrutide moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- HbA1c (Hemoglobin A1c) — ↓ expected to fall
Falling HbA1c is the compound working. Expect it.
What to do: Baseline and 12 weeks. It moves slowly by design — a 4-week retest tells you very little. - Fasting Insulin — ↓ expected to fall
Insulin sensitivity improves as weight falls and the incretin effect restores first-phase insulin release.
What to do: Useful alongside HbA1c; the two together read the trend properly. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to fall
Triglycerides in particular fall with weight loss and improved insulin sensitivity.
What to do: Re-check at 12 weeks rather than chasing early numbers. - Lipase — ↑ expected to rise
Lipase and amylase can rise without pancreatitis on this class. An isolated mild elevation in someone with no symptoms is common.
What to do: Severe, persistent abdominal pain radiating to the back is the thing that matters, not the number. Symptoms decide, not a mild enzyme rise. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Rapid weight loss and reduced intake shift electrolytes and kidney markers; dehydration from nausea or vomiting shows up here first.
What to do: Worth a baseline. If you have been vomiting, this is the panel that catches the consequence. - Ferritin — ↓ expected to fall
Not the drug — the eating. Sharply reduced intake drops iron, B12 and protein intake with it, and this is the most commonly missed consequence of a good response.
What to do: Check ferritin and B12 at 12 weeks. Muscle loss and hair shedding on a GLP-1 is very often a nutrition problem wearing a drug's name.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for Retatrutide — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →The pattern with this class is that the frightening-looking numbers (lipase) are usually fine and the boring ones (ferritin, B12) are where the real damage happens.
Bloodwork to run alongside Retatrutide
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Baseline before the most potent agent in the class |
| Fasting Insulin | The earliest marker of the metabolic change |
| Lipase | Pancreatitis monitoring, as with every incretin |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes |
The On a GLP-1 (Semaglutide / Tirzepatide) panel covers these in one order — 11 markers, $148.05 with the discount applied.
Check results you already have → · All 102 markers A–Z
Retatrutide — frequently asked questions
What is retatrutide?
Retatrutide is an investigational once-weekly triple agonist that activates GIP, GLP-1 and glucagon receptors. It's being developed by Eli Lilly and is not yet FDA-approved.
How does retatrutide work?
It activates three pathways at once: GLP-1 and GIP (appetite, insulin, metabolic effects) plus glucagon, which is thought to raise energy expenditure and reduce liver fat — the combination behind its large trial effects.
How much weight can you lose on retatrutide?
In Phase 3 TRIUMPH trials, the 12 mg dose produced roughly 24–29% average weight loss depending on the study and population — among the highest reported for a medication. It remains investigational and results vary.
Is retatrutide FDA-approved?
No. As of 2026 retatrutide is still investigational and completing its Phase 3 program. There is no approved product, no approved dosing, and anything sold as retatrutide outside a trial is unapproved.
Retatrutide vs tirzepatide vs semaglutide?
Semaglutide targets one pathway, tirzepatide two, retatrutide three. Retatrutide has shown the largest trial weight loss (~24–30%) but is the least mature — the other two are FDA-approved with more long-term data.
What are the side effects of retatrutide?
In trials, mostly GI effects (nausea, vomiting, diarrhea), worst during dose escalation. Because it adds glucagon activity, heart rate and glucose are being watched closely. Long-term safety is still being established.
References & further reading
- Lilly: retatrutide Phase 3 obesity trial results (investor release)
- Retatrutide up to 30.3% average weight loss in Phase 3 TRIUMPH-1 (AJMC)
- FDA: concerns with unapproved GLP-1 drugs used for weight loss
Want Coach Cam's exact Retatrutide protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What Retatrutide is used for
Retatrutide appears under 2 goals in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.